Evidence map›Paper›PMID 40912922›Full record

ArticleThe FEBS journal2026

Modifying inhibitor specificity for homologous enzymes by machine learning.

Dor S Gozlan, Reut Meiri, Gili Shapira, Matt Coban, Evette S Radisky, Yaron Orenstein, Niv Papo

Abstract read
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dor S GozlanAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0009-0001-1708-3098
Reut MeiriDepartment of Computer Science, Bar-Ilan University, Ramat Gan, Israel.
Gili ShapiraAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Matt CobanDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.
Evette S RadiskyDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.ORCID 0000-0003-3121-109X
Yaron OrensteinDepartment of Computer Science, Bar-Ilan University, Ramat Gan, Israel.ORCID 0000-0002-3583-3112
Niv PapoAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0000-0002-7056-2418

Funding

Israel Cancer Research Fund 846497Rosetrees Trust OoR2022/100004United States-Israel Binational Science Foundation 2019303Worldwide Cancer Research 20-0238
6 · The paper itself

Abstract

Selective inhibitors are essential for targeted therapeutics and for probing enzyme functions in various biological systems. The two main challenges in identifying such protein-based inhibitors lie in the extensive experimental effort required, including the generation of large libraries, and in tailoring the selectivity of inhibitors to enzymes with homologous structures. To address these challenges, machine learning (ML) is being used to improve protein design by training on targeted libraries and identifying key interface mutations that enhance affinity and specificity. However, such ML-based methods are limited by inaccurate energy calculations and difficulties in predicting the structural impacts of multiple mutations. Here, we present an ML-based method that leverages HTS data to streamline the design of selective protease inhibitors. To demonstrate its utility, we applied our new method to find inhibitors of matrix metalloproteinases (MMPs), a family of homologous proteases involved in both physiological and pathological processes. By training ML models on binding data for three MMPs (MMP-1, MMP-3, and MMP-9), we successfully designed a novel N-TIMP2 variant with a differential specificity profile, namely, high affinity for MMP-9, moderate affinity for MMP-3, and low affinity for MMP-1. Our experimental validation showed that this novel variant exhibited a significant specificity shift and enhanced selectivity compared with wild-type N-TIMP2. Through molecular modeling and energy minimization, we obtained structural insights into the variant's enhanced selectivity. Our findings highlight the power of ML-based methods to reduce experimental workloads, facilitate the rational design of selective inhibitors, and advance the understanding of specific inhibitor-enzyme interactions in homologous enzyme systems.

Indexed as

Machine LearningMatrix Metalloproteinase InhibitorsTissue Inhibitor of Metalloproteinase-2HumansMatrix Metalloproteinase 1Matrix Metalloproteinase 3Matrix Metalloproteinase 9Matrix MetalloproteinasesModels, MolecularProtein BindingSubstrate SpecificityMatrix Metalloproteinase 1Matrix Metalloproteinase 3Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMatrix MetalloproteinasesTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2deep mutational scanningmatrix metalloproteinasesneural networksprotein engineeringprotein–protein interactions

Identifiers

PMID40912922
PMCPMC12914771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.